| Assessing the predictive role of tumor sidedness in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) treated with first-line doublets + anti-EGFRs/bevacizumab (bev) or triplet + bev: An individual patient data pooled analysis of 10 randomized clinical trials. |
Germani MM |
Cremolini C |
| J Clin Oncol 43 (no. 16_suppl): 3538 |
Abstract |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3538 |
|
|
| The prognostic and predictive role of HER2 amplification/overexpression and HER2 mutations in metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab/anti-EGFRs: An individual patient data pooled analysis of eight randomized trials |
Germani MM |
Cremolini C |
| J Clin Oncol 43 (no. 16_suppl): 3537 |
Abstract |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3537 |
|
|
| 100P Real-world insights in precision oncology: First data of the comprehensive clinico-genomics database network AIO-BNHO-CONNECT (AIO-TF-0122) in Germany. |
Collienne M |
Loges S |
| ESMO Open 9 (suppl 6) |
Abstract |
2024 |
|
|
CONNECT |
AIO-TF-0122 |
| doi.org/10.1016/j.esmoop.2024.103840 |
|
|
| Corrigendum to “Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)”: [ESMO Open 7 (2024) 100552]. |
Hartlapp I |
Kunzmann V |
| ESMO Open 9 (5) |
Sonstige |
2024 |
|
Pankreaskarzinom
|
NEOLAP |
AIO-PAK-0113 |
|
|
|
| Corrigendum to “Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)”: [ESMO Open 7 (2024) 100552]. |
Hartlapp I |
Kunzmann V |
| ESMO Open 9 (10) |
Sonstige |
2024 |
|
Pankreaskarzinom
|
NEOLAP |
AIO-PAK-0113 |
|
|
|
| Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial. |
Dorman K |
Kullmann F |
| Lancet G&H 9 (10): 935-43 |
Vollpublikation |
2024 |
|
Pankreaskarzinom
|
ALPACA |
AIO-PAK-0114 |
| doi.org/10.1016/S2468-1253(24)00197-3 |
|
|
| Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI. |
Alig AHS |
Heinemann V |
| ESMO Open 9 (9): 103677 |
Sonstige |
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
VOLFI |
AIO-KRK-0109 |
| www.esmoopen.com/article/S2059-7029(24)01446-7/fulltext |
|
|
| Durvalumab and tremelimumab versus doxorubicin in previously untreated patients with advanced or metastatic soft tissue sarcoma: Patient-reported outcomes (PROs) of the randomized phase II MEDISARC study (AIO-STS-0415). |
|
|
| J Clin Oncol 42 (suppl 16) |
|
2024 |
|
Weichteilsarkome
|
|
|
| ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.11519 |
|
|
| Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial. |
|
|
| JAMA Oncol |
|
2024 |
|
Urothelkarzinom
|
|
|
| doi.org/10.1001/jamaoncol.2024.0938 |
|
|
| Molecular testing in patients with advanced NSCLC from 2016-23 (Prospective German Registry CRISP, AIO-TRK-0315). |
|
|
| Ann Oncol 35 (Supplement 2, 1388P): 870 |
|
2024 |
|
Thorakale Onkologie
|
|
|
| doi.org/10.1016/j.annonc.2024.08.1443 |
|
|
